Recombinant Human IGFBP6 protein (Myc Tag, His Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
Myc Tag, His Tag
Activity
not tested
Cat no : Eg0087
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <1.0 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human IGFBP6 protein Arg28-Gly240 (Accession# P24592) with a Myc tag and a His tag at the C-terminus. |
| GeneID | 3489 |
| Accession | P24592 |
| PredictedSize | 28.2 kDa |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain.It’s known for its identical protein binding activity and insulin-like growth factor II (IGF-II) binding activity. It plays a role in cell migration and positively regulates the stress-activated MAPK cascade. As a component of the insulin-like growth factor binary complex, IGFBP6 helps modulate the availability and activity of IGFs in the body. IGFBP6 has been implicated in obesity and serves as a biomarker for several conditions, including breast cancer, in situ carcinoma, leiomyoma, and neovascular inflammatory vitreoretinopathy. Research has shown that IGFBP6 can influence tumor progression and response to treatment in various cancer types, such as glioblastoma, ovarian cancer, and prostate cancer.
References:
1.Liso, Arcangelo et al. International journal of molecular sciences vol. 23,8 (2022). 2.Piscazzi, Annamaria et al. Oncology letters vol. 23,6 (2022): 185. 3.Su, Meiming et al. Nature cardiovascular research vol. 4,2 (2025): 145-162.